Clinical Scorecard: Efficacy of Trametinib as a Second-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring KRAS G12C Mutations: A Retrospective Study of 20 Cases from a Single Center
At a Glance
Category
Detail
Condition
Key Mechanisms
Inhibition of MEK1/2 to block the RAS-RAF-MEK-ERK signaling pathway (source needed).
Target Population
Care Setting
Key Highlights
Objective response rate (ORR) of 27.8% and disease control rate (DCR) of 72.2% (source needed).
Median progression-free survival (PFS) of 3.8 months and median overall survival (OS) of 8.6 months (source needed).
Absence of bone metastasis and PD-L1 expression ≥1% associated with improved outcomes (source needed).
Common adverse reactions included rash (35%), diarrhea (25%), and fatigue (20%) (source needed).
No grade 4 or higher adverse reactions or treatment-related deaths observed (source needed).
Guideline-Based Recommendations
Diagnosis
Management
Trametinib 2 mg orally once daily as second-line treatment after progression on first-line therapy (source needed).
Monitoring & Follow-up
Risks
Patient & Prescribing Data
20 patients with advanced KRAS G12C-mutant NSCLC
Trametinib demonstrated anti-tumor activity with manageable toxicity
Clinical Best Practices
Consider trametinib for patients with KRAS G12C mutations who have progressed after first-line therapy (source needed).
Evaluate PD-L1 expression and presence of bone metastasis when assessing treatment response (source needed).
